Fig. 6.

TTFields in combination with anti-PD-1 are therapeutically effective in murine colon cancer model. a Ten-week-old female Balb/c mice bearing 60 mm³ subcutaneous CT-26 tumors were treated with TTFields for 14 days, with a 3-day break (days 13–16). Mice received an I.P. injection of anti-PD-1 (αPD-1) or Rat IgG2a, as indicated in the scheme. b At the end of the experiment, tumor volume was measured using Vernier calipers. N = 2, and the results are reported as mean ± SD of two pooled independent experiments with total of 5–11 mice per group. Tumors were harvested and analyzed using flow cytometry for the percentages (c–e) and PD-L1 expression levels (f–h) of tumor (c, f) CD45+ cells, d, g dendritic cells, e, h macrophages. Percentages of i CD3+CD8+, j CD3+CD4+, and k Foxp3+CD3+CD4+TILs. P values were determined using two-way ANOVA with Tukey’s post-test for (b) or unpaired two-tailed t test for (c–k). *P < 0.05; **P < 0.01; ***P < 0.001